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The effect of uremia and transplantation on lymphocyte sub-
populations. The in Vitro immune response of uremic and trans-
planted patients was studied by determining lymphocyte surface
and functional markers. Because of lymphopenia, the absolute
number of T and B cells was diminished in uremia and trans-
plantation. The uremic state had a profound effect on T cell
mitogenic response, while the relative number (%) of T cells was
not reduced. B cell responses and relative numbers were signifi-
cantly diminished. The early posttransplant period was associated
with a significant reduction in both T and B cell response and
relative numbers. All indexes returned toward normal late in the
posttransplant course with reduction of immunosuppression and
cessation of the uremic state. Horse anti-human lymphocyte globu-
lin treatment caused a significant reduction in T cells and an
increase in B cells. Prednisone therapy did not appear to influence
the relative number of the lymphocyte subpopulation but did
reduce the mitogenic responses. Changes in surface or functional
markers did not prove useful in predicting rejection episodes in
transplanted patients.
Effet de l'urémie et de Ia transplantation sur les sous-populations
lymphocytaires. La réponse immune in Vitro de malades urémiques
et transplantés a été étudiée par Ia determination des marqueurs de
surface et de fonction des lymphocytes. Le nombre absolu des
cellules T et B est diminué dans l'urémie et Ia transplantation en
raison de Ia lymphopénie. L'état urémique a un effet important sur
Ia réponse mitogénique des cellules T alors que leur nombre relatif
(%) n'est pas diminué. Les réponses des cellules B et leur nombre
relatif sont significantivement diminués. La période immediate-
ment consecutive a Ia transplantation est associée a une reduction
significative a Ia fois des réponses et des nombres relatifs des
cellules T et B. Tous ces paramètres ne reviennent a des valeurs
normales que tard dans I'évolution après Ia transplantation, lors de
Ia diminution de I'immunosuppression et de Ia cessation de l'état
urémique. Le traitement par I'ALG determine une diminution
significative des cellules T et une augmentation des cellules B. La
prednisone ne semble pas influencer le nombre relatif des diffé-
rentes populations de lymphocytes mais rCduit les réponses mito-
géniques. Les modifications des marqueurs de surface et de fonc-
tion ne sont pas rCvélCes utiles pour prévoir des episodes de rejet
chez les malades transplantés.
The plurality of the immune system is well estab-
lished, At least two lymphocyte subpopulations exist.
The bone marrow-derived lymphocyte (B cell) is re-
sponsible for the humoral immune reaction and can
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cause target cell killing in the presence of specific
antibody. The thymus-derived lymphocyte (T cell)
is responsible for cell-mediated immunity and im-
munologic memory, and provides a helper function
to some B cell responses. These lymphocyte sub-
populations can be identified by specific cell mem-
brane characteristics (surface markers) [1], and by
their response to specific mitogens (functional mark-
ers) [2].
The uremic state has a profound inhibitory effect
on the immune response of humans and experimental
animals. Skin hypersensitivity and antibody response
to various allergens are decreased [3, 4] and allograft
survival is increased [5, 6]. The production of
lymphokines is reduced [7, 8], and phagocytosis is
impaired [9]. In vitro, the transformation of lym-
phocytes into lymphoblasts in response to antigens is
reduced [3], while their response to mitogens is varia-
bly reported to be increased [10], normal [11] or
decreased [12]. In addition, uremic serum is capable
of suppressing mitogen response in vitro [13].
Successful renal transplantation appears to reverse
the influence of uremia on the immune system, but
adds in its place rather potent and long-term im-
munosuppressive agents whose effects are not well
understood. The purpose of this study was to identify
the lymphocyte subpopulations and measure their
responses in uremic and transplanted patients in or-
der to determine the effect of these states on immune
function.
Methods
The patients studied included 1) 30 chronic uremic
patients with serum creatinine concentrations above
5 mg/l00 ml; 2)60 transplanted patients of which 34
were studied less than three months after trans-
plantation, and 30 were studied more than three
months after transplantation; 3) 3 1 control subjects.
All patients receiving allografts were treated with
prednisone (from 200 to 10 mg/day) and azathio-
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prine. The azathioprine was given in a dose of 3
mg/kg of body wt and adjusted to avoid significant
leukopenia. As an immunosuppressive adjuvant, 11
patients out of the 34 studied in the first three months
after transplantation were treated with horse anti-
human lymphocyte globulin (AHLG, Behringwerke,
Germany) in a dose of 15 mg/kg of body wt i.v. per
day. AHLG therapy was continued for three weeks if
no serious allergic or other complication to this treat-
ment appeared [14].
To determine the effect of immunosuppression on
lymphocyte markers, the results from transplanted
patients on various treatment regimens were divided
into three groups: group I: high-dose steroid (>30
mg of prednisone/day) and AHLG treatment; group
2: high-dose steroid treatment without AHLG treat-
ment; group 3: low-dose steroid treatment (<30 mg
of prednisone/day). Some patients were studied at
different times and also in various treatment groups.
The majority of patients in groups I and 2 were tested
early in the posttransplant period, but group 2 also
included some patients being treated for rejection.
In addition, to determine if surface or functional
markers were of help in predicting rejection, the re-
sults from 12 patients studied within one week before
or after a rejection episode were compared to those
obtained when they were rejection-free for at least
two weeks, A third group of 16 patients who did not
experience a rejection episode during their trans-
plantation course also was studied, All of these
patients were receiving more than 30 mg of pred-
nisone per day. None were receiving AHLG during
these assays.
Lymphocyte preparation. Lymphocytes were sepa-
rated from whole heparinized blood on a Ficoll-Iso-
paque gradient (Nygaard, Oslo, Norway) as de-
scribed by BØyum [15]. The cell layer aspirated from
the plasma gradient interface was washed three times
in phosphate-buffered saline (PBS), and the number
of viable cells remaining was determined by the ex-
clusion of trypan blue. The cells were suspended in
minimal essential medium containing 10% heat-in-
activated AB serum, antibiotics and 1% Hepes buffer
(MEM). This technique usually gave a lymphocyte
yield in excess of 80%.
Surface markers for lymphocyte subpopulations.
The number of T cells was determined by the spon-
taneous formation of rosettes with sheep red blood
cells (SRBC) by a modification of the technique de-
scribed by Jondal, HoIm and Wigzell and others [16,
17]. Fresh SRBC's in Alsever's solution were washed
thrice and 0.01 ml of the packed cells was added to 2
ml of fetal calf serum previously adsorbed thrice with
SRBC's. A part (0.25 ml) of the suspension was in-
cubated with 0.25 ml of lymphocytes in a concentra-
tion of 5 X 106 cells/mI in MEM, The mixture was
incubated for 30 mm at 37°C and then centrifuged
for 5 mm at 200 X g at 4°C. The cells were left as a
pellet at 4°C overnight. Three drops of methylene
blue were added, and the cell pellet was then gently
resuspended with a pasteur pipet. A drop of the sus-
pension was placed on a glass slide and carefully
covered with a glass slip. Two hundred cells were
counted and the percent of lymphocytes binding
more than two erythrocytes was determined.
The number of B cells was measured by the pres-
ence of surface membrane immunoglobulin (Smig)
[171. A fresh pellet of 2.5 X 106 lymphocytes was
resuspended in 0.25 ml of multispecific fluorescein-
labeled sheep anti-human immunoglobulin serum
(Behringwerke, Germany) diluted with PBS to 1:4.
The mixture was incubated for 30 mm at room tem-
perature and then washed three times at 4°C with
PBS containing 0.2% sodium azide. The percent of
cells with SmIg out of 200 total cells was counted
with the aid of an epi-illuminated fluorescence and
phase microscope. White blood cell counts and dif-
ferential count of the peripheral blood were deter-
mined and the absolute numbers of T and B cells
were calculated.
Functional markers for lymphocyte subpopulat ions.
The T cell response was determined by the mitogenic
stimulation by phyto-hemagglutinin (PHA, Well-
come Laboratories, England) used in a dilution of
1: 100 and Concanavalin A (Con A, Miles, Yeda,
Israel) in a concentration of 5 tg/ml [2]. B cell re-
sponse was determined by stimulation with rabbit
anti-human 32 microglobulin (Anti-2m) (Dakopatt
reagents, Denmark), a specific B cell mitogen [18].
Anti-2m was used in a dilution of 1:4.
Culture conditions and assay for DNA synthesis.
Cells were cultured in 0.2 ml of MEM in microtiter
plates (3040, Falcon, USA). Triplicate cultures of
each combination of 150,000 cells per well [19] were
incubated at 37°C in a humidified atmosphere of 5%
CO2 in air for three days. Twenty-four hours before
harvest, 1Ci of 3H-thymidine was added per culture.
Cells were harvested with a semi-automatic harvest-
ing machine (Skatron, Lierbyen, Norway) and the
amount of thymidine incorporated into DNA meas-
ured in a scintillation spectrophotometer (Inter-
technique, N anoteknik, Sweden). The arithmetic
mean and SEM of triplicate cultures were calculated
and the net increase in cpm's was determined (net
increase cpm's = cpmstlmulated — cpmnonstlmulated).
Results
Surface markers. Both uremic and transplanted
patients were lymphopenic. Therefore, the total num-
ber of T and B cells was significantly reduced in both
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states (P < 0.05, Fig. 1). The proportion (%) of I
cells was normal in uremic patients but significantly
reduced in the early posttransplantation period (P <
0.05). In patients studied three months after trans-
plantation, the proportion of T cells was the same as
in the controls, but because of persistent lympho-
penia the total count remained suppressed.
The proportion of B cells was reduced in uremic
patients (P < 0.01) and in the early post-
transplantation period (P < 0.05). The B cell counts
remained reduced three months following trans-
plantation (P < 0.001).
Functional markers. Although the relative number
of T cells was normal in uremic patients, I cell func-
tion as measured by the response to PHA (Fig. 2) and
Con-A (Fig. 3) was significantly reduced (PHA, P <
0.00!; Con-A, P <0.01). The response to theseT cell
mitogens was reduced, but not significantly, in the
early posttransplantation period, although it was sig-
nificantly higher than in uremic patients. Three
months after successful transplantation, the T cell
responses were normal.
The B cell response to anti-132m (Fig. 4) was re-
duced in the uremic patients (P < 0.01) and during
the early posttransplant period (P < 0.001). This
response normalized in patients studied three months
after transplantation.
Effect of immunosuppression on lymphocyte sub-
populations. The results are summarized in Table 1.
There was a significantly lower response to mitogens
during treatment with high-dose steroids (group 2)
when compared to low-dose steroid treatment (group
Transplanted
<3mo. >3mo.
Fig. 2. Mitogenic response to PHA.
3). There was no difference in the relative numbers of
T and B cells. The AHLG-treated patients (group 1)
had a significantly lower relative number of T cells
and a significantly increased proportion of B cells
when compared to groups 2 and 3. There was no
significant difference in the mitogenic response be-
tween groups I and 2.
Effect of rejection on lymphocyte subpopulations.
Rejection episodes were not associated with signifi-
cant changes in lymphocyte surface markers (Table
2). Although the functional response to PHA was
somewhat higher in the rejecting group, the differ-
ence was not significant when compared to the results
obtained from the same patients when not rejecting
or from patients who never had a clinical rejection
episode. In addition, of the 17 tests performed in the
12 rejecting patients, the PHA response in nine in-
stances was higher and in eight instances unchanged
or lower than that obtained when the patients were
not rejecting.
Discussion
Although the division of the immune system into
humoral and cellular responses has been known for
many years, recent techniques have allowed identi-
fication of distinct lymphocyte subpopulations re-
sponsible for these functions. Surface membrane
characteristics (surface markers) allow microscopic
identification [16, 17, 20], while specific mitogens
(functional markers) give a relative measure of the
immune function of these cell types [19, 20].
Although several techniques are available, spon-
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Fig. I. Effect of uremia and transplantation on lymphocyte sub-
populations.
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Fig. 3. Milogenic response to Con-A.
taneous formation of rosettes with sheep red blood
cells to identify I cells and immunofluorescent stain-
ing of surface membrane immunoglobulin to identify
B cells appear to be the most reproducible [17]. Care
must be taken when separating lymphocytes from
whole blood to avoid procedures which may alter the
relative number of T or B cells [17]. Removal of
phagocytes by nylon wool filtration or phagocytosis
of iron particles can falsely reduce the number of B
cells, since these are more adherent than T cells [17,
20]. Since monocytes and polymorphonuclear leu-
kocytes can bind immunoglobulin to their surface,
separation techniques which give a high percent of
contamination with these cell types can result in a
false increase in the number of B cells. In our hands
separation of lymphocytes on a single density Ficol-
isopaque gradient followed by three washes in phos-
phate-buffered saline (PBS) did not selectively re-
move any subpopulation. The T and B cell ratio was
the same when counted on whole blood or separated
lymphocytes [21]. Even with this gradient method
there is a higher contamination of the lymphocytes
with PMN and monocytes in uremics, and especially
in transplant recipients. Careful histologic exam-
ination with phase microscopy can eliminate this
source of error.
Mitogens can be used to estimate the immune func-
tion of selective lymphocyte subpopulations since
each mitogen activates either T or B cells. In addi-
tion, mitogen-activated cells polyclonally reveal their
immunological capacity. PHA and Con A activate
only T cells, or possibly different subsets of I cells
[2]. Anti-/32m stimulates B cells to mitosis and immu-
noglobulin synthesis [18], and current evidence sug-
gests that it does not stimulate T cells. Molter and
Persson have shown that anti-92m can induce DNA
synthesis and polyclonal antibody synthesis in athy-
mic nude mouse lymphocytes, while no effect could
be demonstrated on mouse T cells [22]. Ringdén
and MOller found that anti-f32m also induced DNA
synthesis, polyclonal antibody production and in-
tracellular immunoglobulin synthesis in human pe-
ripheral lymphocytes as well as cells from other
lymphoid organs [18]. Whether human T cells also
are activated by anti-/32m has not been definitely de-
termined, but loss of stimulation in B cell depleted
populations strongly supports its specificity [23]. In
addition, all known pure mitogens that have been
carefully studied selectively activate T or B cells [24].
The present study confirms early reports that both
uremic and transplanted patients are significantly
lymphopenic (Fig. 1) [3]. Because of this lympho-
penia, the total number of both T and B cells was
significantly reduced. The relative number of T cells
was normal in uremics, while the B cells were signifi-
cantly reduced.
T cell response as measured by the mitogenic effect
of PHA and Con-A and B cell response to anti-fl2m
was significantly reduced. The finding of reduced
mitogenic T cell response confirms the findings of
Nakhla and Goggin [10], but is in disagreement with
those of Daniels et al [11], and Kasakura and Low-
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Table I. Effect of immunosuppression on lymphocyte subpopulations0
Mitogenic response (net increase cpm X 10-s)T cells B cells
Treatment group % % PHA Con-A Anti-32m
Group! (N = 22)
Prednisone >30mg/day 46.5 27Il 20.5 + 2.9—i 94.9 13.9 40.3 + 12.8 4.6 1.5
andAHLG
I
Group2(N=52)
Prednisone >30 mg/day 54.2 + 2.7 13.8 1.0 86.8 6.7 25.8 3.7 1withoutAHLG
J I e
le c I IGroup3(N=28) d b Ic
Prednisone <30 mg/day 59.6 2.2 — 13.7 0.8 129.8 13.8 62.2 35.6 6.8'
without AHLG
0 Values are mean + SEM. N = number of tests.
° Significant difference by Student's t test: bp < 0.05; P < 0.025; p < 0.005; P < 0.0005.
enstein [12]. These studies used significantly different number of rosette-forming cells also remains the
techniques, which may be responsible for this dis- same following trypsinazation of lymphocytes from
crepancy. Other systems which test T cell response, AHLG-treated patients (unpublished observations).
such as mixed leukocyte culture [25] and organ graft In the present study there also was a decrease in the
survival [5, 6], confirm a defect in T cell function in proportion of T cells and a compensatory increase in
uremia. the proportion of B cells during treatment with
The suppressed B cell response to mitogen has not AHLG. This suggests that significant I cell removal
previously been reported in uremia. Wilson, Kirk- is occurring.
patrick and Talmage [3] have described a reduced Prednisone treatment also has been known to re-
humoral response following typhoid immunization duce the number of T rosettes [28] and may have an
and a diminished immediate skin hypersensitivity to additive effect. Although a reduction in T cells was
various environmental antigens which are indirect noted in the patients treated with high-dose steroids,
measures of B cell function. A simple reduction in it was not significant. Prednisone has an effect on
responding cells cannot explain the impaired re- mitogenic response because T and B cell responses are
sponse to mitogens, as an equal number of uremic significantly reduced when doses exceed 30 mg/day.
and control cells were assayed. This effect has been previously described for I cells
During the early posttransplant period, the relative but not for B cells.
number of T cells is reduced. This appears to be due Changes in surface or functional markers appear to
to AHLG treatment (Table I). This effect could be have no value in predicting graft rejection. This is in
caused by in vivo coating of the lymphocytes and agreement with the findings of Copeland et al [27],
inhibition of the rosetting [26, 27]. Alternatively, but contrary to the results of Dwyer et al [30], who
AHLG may cause an actual reduction of the number found an increase in PHA response preceding rejec-
of T cells. It seems unlikely that coating of AHLG tion to be of value.
inhibits rosetting, since cells coated with AHLG in If the level of mitogenic response can be related to
vivo and detected with a fluorescent anti-horse immu- the overall immune response, uremia appears to be a
noglobulin serum can form rosettes. The relative potent immunosuppressant and has more of an effect
Table 2. Acute rejection and lymphocyte subpoputation0
Mitogenic response/net increaseT cells B cells
Treatment group % % PHA Con-A A2m
12 patients 52.5 + 3.6 17 + 3 108.5 17 28.9 7.5 3.6 1.4
with rejection + I week
(N= 17)
without rejection 46.8 3.2 14.5 1.5 72.2 6.2 24.4 4.4 6.1 2.1(N=23)
16 control patients 55.! + 3.7 16.2 + 2.1 97.8 + 10.3 40.1 9.2 3.0 1.1(N=28)
0 Values are mean + SEM. N = number of sheep.
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than the usual immunosuppressive drugs adminis-
tered after transplantation. The mitogenic responses
returned to normal relatively early in the post-
transplantation period while the patient remained on
relatively high doses of drugs. It is conceivable that
"uremic toxins" cause significant damage to the im-
mune system either at the stem cell level by altering
the production rate or by impeding function by a
direct effect on cell metabolism. This effect appears to
persist even when the uremic lymphocytes are re-
moved from the abnormal environment but dis-
appears quickly following successful transplantation.
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